Skip to main content
Clinical Trials/NCT04714502
NCT04714502
Unknown
Not Applicable

Verification of Biomarkers to Examine Neonatal Asphyxia-induced Hypoxic-ischemic Encephalopathy Study on Neuro-developmental Follow-up at 2 Years A Prospective Multicenter Observational Study for Development of a Diagnostic Test

InfanDx AG4 sites in 1 country144 target enrollmentJuly 2, 2019
ConditionsBirth Asphyxia

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Birth Asphyxia
Sponsor
InfanDx AG
Enrollment
144
Locations
4
Primary Endpoint
Participants with abnormal neuro-developmental status - non-HIE
Last Updated
5 years ago

Overview

Brief Summary

Follow-up of participants of AAMBI1 study at age of at least 2 years. AAMBI1(ClinicalTrials.gov ID: NCT03354208): Verification of biomarkers in a human population for their ability to diagnose the severity of neonatal asphyxia. These biomarkers linked to asphyxia have been identified in animal studies.

Detailed Description

Follow-Up on neuro-developmental status of Study participants of AAMBI1. AAMBI1(ClinicalTrials.gov ID: NCT03354208): The aim of the study is to verify the application of combinations of several laboratory parameters in early postnatal blood samples, for identification of infants, who will suffer from early abnormal neonatal neurological outcome, in a population at risk. The population at risk is defined as term and late preterm (\>36 weeks of gestation) human infants following perinatal hypoxia-ischemia with or without postnatal resuscitation.

Registry
clinicaltrials.gov
Start Date
July 2, 2019
End Date
December 31, 2021
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
InfanDx AG
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Infants previously enrolled in the AAMBI1 study

Exclusion Criteria

  • Missing valid written informed parental consent

Outcomes

Primary Outcomes

Participants with abnormal neuro-developmental status - non-HIE

Time Frame: up to 42 month age

Presence of adverse 2 years neuro-developmental Outcome not attributable to perinatal hypoxic-ischemic brain injury

Participants with normal neuro-developmental status

Time Frame: up to 42 month age

All infants with normal neuro-developmental status

Participants with abnormal neuro-developmental status - HIE

Time Frame: up to 42 month age

Presence of adverse 2 years neuro-developmental outcome likely attributable to perinatal hypoxic-ischemic brain injury

Participants with potentially abnormal neuro-developmental status

Time Frame: up to 42 month age

All infants who do not fulfill outcomes 1, 3 or 4

Study Sites (4)

Loading locations...

Similar Trials